JP2015523364A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523364A5
JP2015523364A5 JP2015520652A JP2015520652A JP2015523364A5 JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5 JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015520652 A JP2015520652 A JP 2015520652A JP 2015523364 A5 JP2015523364 A5 JP 2015523364A5
Authority
JP
Japan
Prior art keywords
thiosulfate
agent
oxoprotective
sepsis
related condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520652A
Other languages
English (en)
Japanese (ja)
Other versions
JP6509112B2 (ja
JP2015523364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049087 external-priority patent/WO2014008273A2/en
Publication of JP2015523364A publication Critical patent/JP2015523364A/ja
Publication of JP2015523364A5 publication Critical patent/JP2015523364A5/ja
Application granted granted Critical
Publication of JP6509112B2 publication Critical patent/JP6509112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520652A 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法 Expired - Fee Related JP6509112B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (3)

Publication Number Publication Date
JP2015523364A JP2015523364A (ja) 2015-08-13
JP2015523364A5 true JP2015523364A5 (enExample) 2016-08-25
JP6509112B2 JP6509112B2 (ja) 2019-05-08

Family

ID=49882592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520652A Expired - Fee Related JP6509112B2 (ja) 2012-07-03 2013-07-02 オキソ関連状態の治療、診断および/またはその進行のモニタリングのための方法

Country Status (7)

Country Link
US (1) US20150174160A1 (enExample)
EP (1) EP2866565A4 (enExample)
JP (1) JP6509112B2 (enExample)
CN (1) CN104582490A (enExample)
AU (2) AU2013286876B2 (enExample)
CA (1) CA2915793A1 (enExample)
WO (1) WO2014008273A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210239678A1 (en) * 2018-04-19 2021-08-05 StickyCell Pty Ltd Leukocyte recruitment in infectious disease
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
AU2023312830A1 (en) * 2022-07-27 2025-02-20 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025531018A (ja) 2022-09-14 2025-09-19 ビオグノシス アーゲー 薬物標的滞留時間を決定し、最適な薬物-標的候補を選択する方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
DK1063228T5 (da) * 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
WO2003104178A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
EP2392321A1 (en) * 2007-06-13 2011-12-07 Jay Pravda Combined composition for rectal administration for the treatment of inflammatory bowel disease
WO2009154800A2 (en) * 2008-06-21 2009-12-23 Webb-Waring Institute Compositions and methods for treating lung disorders
CA2785633C (en) * 2009-12-28 2014-07-15 N.V. Perricone Llc Topical acyl glutathione formulations

Similar Documents

Publication Publication Date Title
Bevc et al. Measurement of breath ammonia for detection of patients with chronic kidney disease
Ren et al. Dynamic change of hydrogen sulfide during global cerebral ischemia–reperfusion and its effect in rats
MX2022006908A (es) Composiciones orales humedas.
Lipinski et al. Early changes in serum creatinine level and estimated glomerular filtration rate predict pancreatic necrosis and mortality in acute pancreatitis: creatinine and eGFR in acute pancreatitis
Smith et al. Animal models of viral hemorrhagic fever
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
Gu et al. Contribution of hydrogen sulfide and nitric oxide to exercise-induced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats
MX2009013683A (es) Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo.
DE602006021768D1 (de) Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
BR112015004878A2 (pt) dispositivo e método para determinar se as condições predeterminadas para medir um primeiro parâmetro fisiológico de um indivíduo são atendidas, e, vestimenta para ser vestida pelo indivíduo
BR112019001144A2 (pt) método e kit para determinar concentração de oxidanteem soluções desinfetantes
Samal et al. Administration of nitrite after chlorine gas exposure prevents lung injury: effect of administration modality
FR2959414B1 (fr) Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
WO2023215880A3 (en) Compositions and methods for gys1 inhibition
Myszka et al. Sodium hydrosulfide moderately alleviates the hallmark symptoms of Duchenne muscular dystrophy in mdx mice
Śledziński et al. Serum cystatin C in relation to fat mass loss after bariatric surgery
JP2012524884A5 (enExample)
KR102219895B9 (ko) 쯔쯔가무시병 진단용 조성물 및 이를 포함하는 키트
MX348303B (es) Métodos y composiciones para la evaluación de lesión renal utilizando ácido hialurónico.
JP2011211907A (ja) にんにくの少臭化処理方法
Abudu et al. The effect of thiocyanate on the Nova ion-selective electrode for magnesium
WO2015070084A3 (en) Nuclear stress response in motor neuron disease and other neurological diseases
UA110689C2 (uk) Спосіб прогнозування рецидивів фібриляції передсердь
Carrillo Esper et al. Procalcitonin as marker of infectious processes in surgery: Current concepts